awmsg logo



sunitinib (Sutent®)


Reference No. 390

Publication date:
13/10/2011


Appraisal information

sunitinib (Sutent®) capsule


Company: Pfizer Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 20/07/2011
AWMSG meeting date: 14/09/2011
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 1111
Ministerial ratification: 11/10/2011

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Sunitinib (Sutent®) is recommended for use within NHS Wales for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pNET) with disease progression in adults. Experience with sunitinib as a first-line treatment is limited. AWMSG is of the opinion that sunitinib (Sutent®) is not suitable for shared care within NHS Wales for the above indication.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download